Webcast ImageWebcast
Depomed at the 27th Annual ROTH Conference (Replay)
03/10/15 at 12:30 p.m. ET
Download Event Supporting Material  NUCYNTA Acquisition Investor Presentation

Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market four FDA-approved products, Gralise®, Cambia®, Zipsor®, and Lazanda®. We actively seek to expand our product portfolio through in-licensing, acquiring or obtaining co-promotion rights to commercially available products or late-stage product candidates that could be marketed and sold effectively with our existing products through our sales and marketing capability. In addition, Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. We have licensed Acuform technology to six pharmaceutical partners and the technology is currently being used in four marketed drugs, including Gralise.

The following are abbreviated descriptions of our products:

Gralise® (gabapentin), a once-daily product for the management of postherpetic neuralgia, Cambia®(diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older,  Zipsor® (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain in adults, and Lazanda® (fentanyl) nasal spray CII for the  management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and who are tolerant to regular opioid therapy for their underlying persistent cancer pain.  See Important Safety Information for Gralise and the black box warnings for CambiaZipsor, and Lazanda.

Recent News> MORE
03/17/15Depomed Announces Termination of Hart-Scott-Rodino Waiting Period for Pending Acquisition of NUCYNTA® Franchise from Janssen PharmaceuticalsPrinter Friendly Version
03/12/15Depomed Secures $575 Million Debt Facility From Deerfield and Pharmakon to Finance the Closing of NUCYNTA® AcquisitionPrinter Friendly Version
03/03/15Depomed To Present At 27th Annual Roth ConferencePrinter Friendly Version
Upcoming and Recent Events> MORE
12:30 p.m. ET
Depomed at the 27th Annual ROTH Conference
LocationLaguna Niguel, CA
Supporting Materials
Download Event Supporting Material Depomed at the 27th Annual ROTH Conference Presentation
10:00 a.m. ET
Depomed at the RBC 2015 Healthcare Conference
LocationPalace Hotel
New York, NY
Supporting Materials
Download Event Supporting Material Depomed at the RBC 2015 Healthcare Conference Presentation
1:30 p.m. PT
Q4 2014 Depomed Earnings Conference Call
Supporting Materials
Download Event Supporting Material Depomed Q4 2014 Earnings Conference Transcript

DEPO (Common Stock)

Change (%)
 + 0.16 (0.71%)
Market Cap

Data as of 03/30/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Powered By EDGAR Online, Inc.